Search results for "alcoholic"

showing 10 items of 509 documents

Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients.

2001

- Vitamin B12 serum levels and markers for alcohol consumption were determined in 80 male alcohol-dependent patients. Spearman correlation coefficients (r(S)) were calculated. Significant positive correlations between vitamin B12 and hepatic enzyme values were found (gamma-glutamyltransferase: r(S) = 0.58; alanine aminotransferase: r(S) = 0.43; aspartate aminotransferase: r(S) = 0.47; glutamate dehydrogenase: r(S) = 0.43; all P:0.001). Therefore, for a proper interpretation of vitamin B12 levels, it may be clinically relevant to take markers of hepatocellular damage into account.

AdultErythrocyte IndicesMalemedicine.medical_specialtyCarbohydrate deficient transferrinAspartate transaminaseStatistics NonparametricGlutamate DehydrogenaseInternal medicineBlood plasmamedicineHumansCyanocobalaminVitamin B12Aspartate AminotransferasesLiver Diseases AlcoholicRetrospective StudiesbiologyGlutamate dehydrogenaseTransferrinnutritional and metabolic diseasesAlanine TransaminaseGeneral Medicinegamma-GlutamyltransferaseMiddle AgedAlcoholismVitamin B 12EndocrinologyAlanine transaminaseLiverToxicitybiology.proteinBiomarkersAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver

2017

Abstract Background and Aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at‐risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population‐based Dallas Heart Study (DHS). Re…

AdultGenetic MarkersLiver CirrhosisMalenonalcoholic fatty liver diseaseNon-alcoholic Fatty Liver Diseaseinsulin resistanceHumansgeneticsProspective StudiesAdaptor Proteins Signal TransducingSettore MED/12 - GastroenterologiafibrosisMembrane ProteinsOriginal ArticlesLipaseMendelian Randomization AnalysisAdipose TissueDiabetes Mellitus Type 2Chronic Diseasemendelian randomizationOriginal ArticleFemaletype 2 diabetesgeneticfibrosiAcyltransferases
researchProduct

Liver transplantation: the Italian experience

2002

Abstract Background. Liver transplantation is the standard treatment for patients with end-stage liver disease no longer responsive to conventional medical treatment Aims . To report the longterm experience of liver transplantation in Italy. Patients and Methods . Data were obtained retrospective by means of a multiple-item form collected from 15 Italian liver transplant centres. The filing centre was centralized. Results . A total of 3323 liver transplants were performed on 3026 patients, with a cumulative proportional survival of 72.4%. Three, 5 and 10 years' patient survival rates were 72.3%, 68.8% and 61.3%, respectively. The most common indication for liver transplantation were hepatit…

AdultGraft RejectionMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisAdolescentmedicine.medical_treatmentLiver transplantationGastroenterologyLiver diseaseRecurrenceInternal medicinePrevalenceMedicineHumansAgedRetrospective StudiesLiver transplantationHepatologybusiness.industryLiver DiseasesPatient SelectionGastroenterologyHepatitis CHepatitis BMiddle Agedmedicine.diseaseTransplantationSurvival RateItalyFemaleHepatitis D virusbusinessLiver disease
researchProduct

"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".

2022

Objectives Non-alcoholic fatty liver disease (NAFLD) is strongly associated with cardiovascular disease in the general population. We aimed to assess the impact of NAFLD and liver fibrosis on intermediate-high cardiovascular risk in people living with HIV. Methods We included people living with HIV from three cohorts. NAFLD and significant liver fibrosis were defined using transient elastography: controlled attenuation parameter >= 288 dB/m and liver stiffness measurement >= 7.1 kPa, respectively. Cardiovascular risk was assessed with the atherosclerotic cardiovascular disease (ASCVD) risk estimator in patients aged between 40 and 75 years and categorised as low if <5%, borderline …

AdultLiver CirrhosisLiver CirrhosiHIV InfectionsBMIElasticity Imaging TechniqueNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseHumansHIV InfectionPharmacology (medical)Prospective StudiesNon-alcoholic Fatty Liver Disease.AgedASCVD score; BMI; controlled attenuation parameter; HIV mono-infection; transient elastographyASCVD scoreRisk FactorHealth PolicyHIV mono-infectionHeart Disease Risk FactorMiddle Agedtransient elastographycontrolled attenuation parameterProspective StudieInfectious DiseasesLiverCardiovascular DiseasesHeart Disease Risk FactorsElasticity Imaging TechniquesHumanHIV medicineREFERENCES
researchProduct

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

2018

AbstractLiver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non-invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum microRNA biomarkers with altered levels in NAFLD patients. In the present study, we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort. Moreover, miR-192, -27b, -22, -197 and -30c appeared specific for NAFLD, when compared wi…

AdultLiver CirrhosisMale0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineSeverity of Illness Indexdigestive systemArticleCohort Studies03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicinemicroRNANonalcoholic fatty liver diseasemedicineHumansCirculating MicroRNAlcsh:ScienceSerum micrornaAgedLiver injuryMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RLiquid BiopsyMiddle AgedPrognosismedicine.diseasedigestive system diseasesCirculating MicroRNA030104 developmental biologyLiverLiver biopsyCohortDisease ProgressionFemalelcsh:QbusinessBiomarkers
researchProduct

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

2018

Background & Aims The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. Methods We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fi…

AdultLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtysteatohepatitisSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineHumansMedicineIn patientProspective StudiesKeratin-18Hepatologymedicine.diagnostic_testbusiness.industryFatty liverExternal validationReproducibility of ResultsMiddle Agedmedicine.disease3. Good health030104 developmental biologyItalyLiverROC Curvenon-invasive markerLiver biopsyCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatohepatitisfibrosibusinessAlgorithmsBiomarkersLiver International
researchProduct

Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys

2019

Background: The information on the geographical characteristics of chronic liver diseases (CLD) in Italy is out-dated. Aim: To provide up-dated information on the geographical pattern of patients with CLD born in Italy. Methods: Patients with CLD were enrolled in two national surveys performed in 2001 and 2014, which prospectively recruited subjects aged ≥18 years referring to Italian liver units located throughout the country that apply a similar clinical approach and analytical methods. Results: The total number of patients enrolled was 11,676. Alcohol-related CLD was more frequently observed in northern/central areas (25.0% vs. 20.7%, p < .001), while HBV-related (15.4% vs. 13.3%, p =…

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesAlcohol; Chronic hepatitis; Geographical pattern; HBV; HCV; Liver cirrhosisLiver cirrhosiGeographical patternHepatitis B ChronicChronic hepatitisSurveys and QuestionnairesEnvironmental healthHBVInternal MedicineHumansMedicineLiver Diseases AlcoholicChronic hepatitisAgedGeographybusiness.industryLiver DiseaseLiver DiseasesHepatitis C ChronicMiddle Agedrespiratory tract diseasesItalyChronic DiseaseHCVChronic hepatitiFemalebusinessAlcoholHuman
researchProduct

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

2013

Abstract Background Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysisLogistic regressionGastroenterologyCohort StudiesHepatitis B ChronicLiver Cirrhosis AlcoholicRisk FactorsInternal medicinemedicineHumansIn patientAspartate AminotransferasesChemoembolization TherapeuticAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyAcute Kidney InjuryHepatitis C ChronicLiver Failure AcuteMiddle Agedmedicine.diseaseUniversity hospitalTumor BurdenSurgeryLogistic ModelsTreatment OutcomeDoxorubicinHepatic EncephalopathyHepatocellular carcinomaMultivariate AnalysisToxicityFemaleChemical and Drug Induced Liver InjuryIdarubicinbusinessDigestive and Liver Disease
researchProduct

Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis

1996

Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations (P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However, patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2—3 fold) than those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher cathepsin D serum mass concentrations (m…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularClinical BiochemistryeducationLiver cirrhosis tumor markrersCathepsin DBiologymedicine.disease_causeCathepsin DImmunoenzyme TechniquesInternal medicinemedicineHumansAgedchemistry.chemical_classificationmedicine.diagnostic_testHepatitis AlcoholicBiochemistry (medical)Liver NeoplasmsGeneral Medicinehepatocellular carcinomaMiddle Agedmedicine.diseaseEnzymeEndocrinologychemistryImmunoassayHepatocellular carcinomaFemalealpha-FetoproteinsSteatosisCarcinogenesisLiver function tests
researchProduct